drugset / Trial / NCT01129518

Can we Reduce the Number of Vaccine Injections for Children?

NCT01129518 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

This open label randomised controlled study will evaluate the induction of immunity following varying schedules of vaccination with glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccines in infancy. 498 infants will be enrolled in this multi-centre trial. Participants will receive either 0, 1, or 2 priming doses of a MenC-CRM197 conjugate vaccine or 1 priming dose of a MenC-TT conjugate vaccine in the first year of life, with all groups receiving a dose of a combination Hib-MenC-TT vaccine at 12 months, as well as all other concurrent routine vaccinations. All groups will also be further divided into 2 groups to receive their routine vaccines in either consistent or alternating limbs to assess the immune response to the concurrent infant routine immunisations administered in consistent versus alternating limbs. Immune responses will be assessed at 5, 12, 12months +6 days, 13 and 24 months of age.

Timeline

Start
2010-06
Primary completion
2013-07
Completion
—

Outcome

Met primary endpoint

paper The primary objective was met: PMID 25832102 ↗

paper with a corresponding difference in the mean log10 MenC rSBA of 0.35 (0.17 to 0.53) that showed superiority PMID 25832102 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine Vaccine — Intramuscular